AR069188A1 - Compociones y metodos para tratar una hemorragia uterina disfuncional - Google Patents
Compociones y metodos para tratar una hemorragia uterina disfuncionalInfo
- Publication number
- AR069188A1 AR069188A1 ARP080104830A ARP080104830A AR069188A1 AR 069188 A1 AR069188 A1 AR 069188A1 AR P080104830 A ARP080104830 A AR P080104830A AR P080104830 A ARP080104830 A AR P080104830A AR 069188 A1 AR069188 A1 AR 069188A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- dysfunctional uterine
- uterine hemorrhage
- patient
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 8
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- -1 methyloxy, formyloxy, acetoxy Chemical group 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- JVBGZFRPTRKSBB-MJBQOYBXSA-N Telapristone acetate Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(C(=O)COC)OC(C)=O)=CC=C(N(C)C)C=C1 JVBGZFRPTRKSBB-MJBQOYBXSA-N 0.000 abstract 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000044 progesterone antagonist Substances 0.000 abstract 1
- 102000003998 progesterone receptors Human genes 0.000 abstract 1
- 108090000468 progesterone receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El objeto de la presente está dirigido al campo de la terapia hormonal, se refiere a métodos de tratamiento de una hemorragia uterina disfuncional, el tratamiento y/o la prevencion de anemia en pacientes con hemorragia uterina disfuncional. Composiciones para la práctica de los métodos que comprenden antagonistas de progesterona, métodos para identificar nuevos moduladores selectivos del receptor de progesterona para la práctica de los métodos de tratamiento revelados. Reivindicacion 1: Un método de tratamiento de hemorragia uterina disfuncional en una paciente, caracterizado porque comprende administrarle a dicha paciente una cantidad eficaz de una composicion que comprende un compuesto de la formula (1), o una sal aceptable para uso farmacéutico, hidrato o solvato del mismo, en donde: X representa un alquilo, alquenilo, alquinilo, hidrogeno, halo, monoalquilamino o dialquilamino; R1 representa O, NOH o NO-metilo; R2 representa un hidrogeno o acetilo; y R3 representa metiloxi, formiloxi, acetoxi, acetilteonilo, glicimato, viniléter, acetiloximetilo, carbonato de metilo, halogenos, metilo, hidroxi o etiloxi, en donde la cantidad de dicha composicion es eficaz para tratar una hemorragia uterina disfuncional en dicha paciente. Reivindicacion 2: El método de la cláusula 1, caracterizado porque dicho compuesto es CDB-4124. Reivindicacion 11: El método de la reivindicacion 10, caracterizado porque dicho compuesto es administrado por un período de al menos entre aproximadamente uno y aproximadamente seis meses.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98552807P | 2007-11-05 | 2007-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069188A1 true AR069188A1 (es) | 2010-01-06 |
Family
ID=40091934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104830A AR069188A1 (es) | 2007-11-05 | 2008-11-04 | Compociones y metodos para tratar una hemorragia uterina disfuncional |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090118253A1 (es) |
| AR (1) | AR069188A1 (es) |
| CL (1) | CL2008003070A1 (es) |
| TW (1) | TW200927137A (es) |
| WO (1) | WO2009061569A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| EP2545922A1 (en) * | 2011-07-12 | 2013-01-16 | PregLem S.A. | Treatment of excessive menstrual bleeding associated with uterine fibroids |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10512889A (ja) * | 1995-02-02 | 1998-12-08 | シェーリング アクチェンゲゼルシャフト | 機能不全性子宮出血を治療する医薬を製造するためのプロゲステロンアンタゴニスト |
| US6900193B1 (en) * | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| ATE194358T1 (de) * | 1996-05-01 | 2000-07-15 | Us Gov Health & Human Serv | 21-substituierte progesteron derivate als antigestagene |
| IN191020B (es) * | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| JP4898431B2 (ja) * | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| HRP20160689T1 (hr) * | 2007-04-20 | 2016-07-15 | Preglem S.A. | Selektivni modulatori progesterona za tretman uterinog krvarenja |
-
2008
- 2008-10-03 WO PCT/US2008/078684 patent/WO2009061569A1/en not_active Ceased
- 2008-10-03 US US12/245,089 patent/US20090118253A1/en not_active Abandoned
- 2008-10-16 CL CL2008003070A patent/CL2008003070A1/es unknown
- 2008-10-24 TW TW097141089A patent/TW200927137A/zh unknown
- 2008-11-04 AR ARP080104830A patent/AR069188A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200927137A (en) | 2009-07-01 |
| US20090118253A1 (en) | 2009-05-07 |
| WO2009061569A1 (en) | 2009-05-14 |
| CL2008003070A1 (es) | 2009-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR071516A1 (es) | Regimenes de dosificacion con antiprogestinas que comprende la administracion de un antagonista de progesterona como el compuesto cdb-4124 | |
| BR112014016085A8 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| SV2010003491A (es) | 2- anilinopurin-8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| AR071419A1 (es) | Composiciones y metodos de tratamiento del cancer de mama | |
| AR070025A1 (es) | Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112014010228A8 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
| ATE537833T1 (de) | Behandlung des mekoniumaspirationssyndroms mit östrogenen | |
| BR112018067906A2 (pt) | métodos de tratamento de depressão usando antagonistas do receptor de orexina-2 | |
| CO7101246A2 (es) | Compuesto de carbamato y preparación y uso de los mismos | |
| BR112014010223B8 (pt) | uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica | |
| CL2008003582A1 (es) | Uso de una composicion farmaceutica que contiene cisteamina o cistamina en la preparacion de un medicamento util para el tratamiento de una enfermedad de higado graso no alcholico (nafld) o esteatohepatitis no alcoholica (nash). | |
| CR9022A (es) | Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias | |
| BR112012020731A2 (pt) | pastilhas gelatinosas suaves com nicotina. | |
| CL2007000345A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes. | |
| MX2018009173A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de esteatohepatitis no alcohólica (nash). | |
| BRPI0921097B8 (pt) | composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto | |
| BR112015013136A2 (pt) | dispositivos de filtração posicionáveis in vivo e métodos relacionados aos mesmos | |
| AR062401A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
| BRPI0916282B8 (pt) | uso de um agonista do receptor-pgi2 no tratamento de insuficiência renal crônica | |
| BR112013002280A2 (pt) | composições farmacêuticas orais de liberação controlada compreendendo blonanseina | |
| AR114216A1 (es) | Composiciones oftálmicas de compuestos de bencimidazol para uso único diario | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |